SG11201804132UA - Eif4-a-inhibiting compounds and methods related thereto - Google Patents
Eif4-a-inhibiting compounds and methods related theretoInfo
- Publication number
- SG11201804132UA SG11201804132UA SG11201804132UA SG11201804132UA SG11201804132UA SG 11201804132U A SG11201804132U A SG 11201804132UA SG 11201804132U A SG11201804132U A SG 11201804132UA SG 11201804132U A SG11201804132U A SG 11201804132UA SG 11201804132U A SG11201804132U A SG 11201804132UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- san diego
- jolla
- compounds
- foiinula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/153—Ortho-condensed systems the condensed system containing two rings with oxygen as ring hetero atom and one ring with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -' Organization International Bureau ... ....,*/ /d (43) International Publication Date .... .....r ,„„0 1 June 2017 (01.06.2017) WIPO I PCT ID Hit (10) WO International 2017/091585 111111111111111111111111111111110111111HIIIIIIIIIIMIIIIIIIIIIIIIII Publication Al Number (51) International Patent Classification: NILEWSKI, Christian; 5940 La Jolla Mesa Drive, La A61K 31/5377 (2006.01) A61K 31/4706 (2006.01) Jolla, CA 92037 (US). MICHELS, Theodore; 4353 A61K 31/4709 (2006.01) Felton St. #3, San Diego, CA 92104 (US). (21) International Application Number: (74) Agent: PINO, Mark, J.; Mintz Levin Cohn Ferris Glovsky PCT/US2016/063353 And Popeo, PC, 701 Pennsylvania Avenue, Nw, Suite 900, Washington, DC 20004 (US). (22) International Filing Date: 22 November 2016 (22.11.2016) (81) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (26) Publication Language: English BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (30) Priority Data: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 62/259,828 25 November 2015 (25.11.2015) US KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 62/334,149 10 May 2016 (10.05.2016) US MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (71) Applicant: EFFECTOR THERAPEUTICS, INC. OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, [US/US]; 11180 Roselle Street, San Diego, CA 92121 SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (US). TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (72) Inventors: ERNST, Justin, T.; 4288 Kerwood Court, San Diego, CA 92130 (US). REICH, Siegfried, H.; 5940 La (84) Designated States (unless otherwise indicated, for every Jolla Mesa Drive, La Jolla, CA 92037 (US). SPRENGEL- kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, ER, Paul, A.; 8706 Gracilior Court, Escondido, CA 92026 TRAN, Chinh; 2736 Bellezza Drive, San Diego, CA TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (US). 92108 PACKARD, Garrick, Kenneth; 4485 Vision TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (US). DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Dr Apt. 6, San Diego, CA 92121 (US). XIANG, Alan, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Xin; 211 Midvale Lane, Irvine, CA 92620 (US). [Continued on next page] Title: EIF4-A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO (54) (57) : The present invention provides synthesis, pharmaceutically acceptable foiinulations and uses of in Foiinula I, compounds accordance with or a stereoi- R4 b 4a somer, tautomer or pharmaceutically acceptable salt thereof. For Foiinula (I) compounds X, Y, R I , R, R 2 3 a, e 3 b R ib , R 4a , R a and R 5 are as defined in the specification. e The inventive Foiinula (I) compounds are inhibitors of N b . R5 % elF4A and fmd utility in any number of therapeutic ap- R3a including but not limited to treatment of in- plications, flammation and various cancers. ••• e e / 1 x .... a 1-1 .4t in GC in 1 - 1 01 0 IN 1 - 1 C ei (T) 0 WO 2017/091585 Al MIONIM011EMIMOIDEDMEIM111111111111111111111111111111 SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, before the expiration of the time limit for amending the GW, KM, ML, MR, NE, SN, TD, TG). Published: claims and to be republished amendments (Rule 48.2(h)) in the event of receipt of — with international search report (Art. 21(3))
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562259828P | 2015-11-25 | 2015-11-25 | |
| US201662334149P | 2016-05-10 | 2016-05-10 | |
| PCT/US2016/063353 WO2017091585A1 (en) | 2015-11-25 | 2016-11-22 | Eif4-a-inhibiting compounds and methods related thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201804132UA true SG11201804132UA (en) | 2018-06-28 |
Family
ID=58720397
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201804132UA SG11201804132UA (en) | 2015-11-25 | 2016-11-22 | Eif4-a-inhibiting compounds and methods related thereto |
| SG10202004793YA SG10202004793YA (en) | 2015-11-25 | 2016-11-22 | Eif4-a-inhibiting compounds and methods related thereto |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202004793YA SG10202004793YA (en) | 2015-11-25 | 2016-11-22 | Eif4-a-inhibiting compounds and methods related thereto |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US9957277B2 (en) |
| EP (2) | EP3380101B1 (en) |
| JP (1) | JP7105691B2 (en) |
| KR (1) | KR20180096644A (en) |
| CN (1) | CN108601788B (en) |
| AU (1) | AU2016359617B2 (en) |
| CA (1) | CA3006041A1 (en) |
| CL (1) | CL2018001411A1 (en) |
| CO (1) | CO2018006475A2 (en) |
| DK (2) | DK3380101T3 (en) |
| EA (1) | EA037370B1 (en) |
| ES (2) | ES2974439T3 (en) |
| FI (1) | FI3888658T3 (en) |
| IL (1) | IL259433B (en) |
| MX (1) | MX2018006443A (en) |
| MY (1) | MY196749A (en) |
| NZ (1) | NZ743453A (en) |
| PE (1) | PE20181303A1 (en) |
| PH (1) | PH12018501073A1 (en) |
| SG (2) | SG11201804132UA (en) |
| TW (1) | TWI731899B (en) |
| WO (1) | WO2017091585A1 (en) |
| ZA (1) | ZA201804070B (en) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015117087A1 (en) | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
| RU2016134947A (en) | 2014-01-31 | 2018-03-01 | Дана-Фарбер Кансер Институт, Инк. | DERIVATIVES OF DIAMINOPYRIMIDINE BENZENESULPHONE AND THEIR APPLICATION |
| JP6832861B2 (en) | 2014-11-17 | 2021-02-24 | セレクター・バイオサイエンシズ・インコーポレイテッド | Phospholipid ether analog as a cancer targeting drug vehicle |
| KR20180049058A (en) | 2015-09-11 | 2018-05-10 | 다나-파버 캔서 인스티튜트 인크. | Cyanothienotriazolodiazepines and their uses |
| JP2018526424A (en) | 2015-09-11 | 2018-09-13 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | Acetamidhienotriazolodiazepines and their use |
| JP2019503338A (en) | 2015-11-25 | 2019-02-07 | ギリアド アポロ， エルエルシー | Fungicidal composition comprising a derivative of 2,4-dioxo-1,4-dihydrothieno [2,3-d] pyrimidine |
| CN108601788B (en) | 2015-11-25 | 2021-10-22 | 效应治疗股份有限公司 | EIF 4A-inhibiting compounds and methods relating thereto |
| PT3380479T (en) | 2015-11-25 | 2023-03-13 | Gilead Apollo Llc | Triazole acc inhibitors and uses thereof |
| CN114957291A (en) | 2015-11-25 | 2022-08-30 | 达纳-法伯癌症研究所股份有限公司 | Bivalent bromodomain inhibitors and uses thereof |
| SI3380480T1 (en) | 2015-11-25 | 2023-04-28 | Gilead Apollo, Llc | Pyrazole acc inhibitors and uses thereof |
| CN108290902B (en) | 2015-11-25 | 2021-08-31 | 吉利德阿波罗公司 | Ester ACC inhibitors and uses thereof |
| CA3062185A1 (en) * | 2017-05-04 | 2018-11-08 | Glenmark Pharmaceuticals S.A. | Substituted bicyclic heterocyclic compounds as nadph oxidase inhibitors |
| BR112019024719A2 (en) | 2017-05-24 | 2020-06-16 | Effector Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR IMPROVED ANTITUMOR IMMUNOLOGICAL RESPONSE |
| US20200392099A1 (en) * | 2018-02-19 | 2020-12-17 | Memorial Sloan-Kettering Cancer Center | Agents and methods for treating dysproliferative diseases |
| CN109503418B (en) * | 2018-12-11 | 2021-06-08 | 河北合佳医药科技集团股份有限公司 | Preparation process of methylhydrazine |
| WO2020172086A1 (en) * | 2019-02-18 | 2020-08-27 | The University Of Toledo | Targeting lasp1, eif4a1, eif4b, and cxc4 with modulators and combinations thereof for cancer therapy |
| CN109971762B (en) * | 2019-04-24 | 2022-12-20 | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | SiRNA of schistosoma japonicum eIF4A gene and application thereof |
| EP4125884A4 (en) * | 2020-03-24 | 2024-04-03 | Effector Therapeutics, Inc. | Eif4a inhibitor combinations |
| CN116547289A (en) * | 2020-10-28 | 2023-08-04 | 上海翰森生物医药科技有限公司 | Polycyclic biological regulator, preparation method and application thereof |
| CN112574078B (en) * | 2020-12-14 | 2022-09-13 | 湖南工程学院 | 2-sulfuryl-2, 3-dihydro-1-indanone and derivatives and synthesis method thereof |
| EP4395775A1 (en) | 2021-09-01 | 2024-07-10 | KHR Biotec GmbH | Cyclopenta[4,5]furo[3,2-c]pyridine derivatives as ras inhibitors for use in the treatment of hyperproliferative diseases or genetic disorders |
| JP2024534184A (en) | 2021-09-01 | 2024-09-18 | カーハーエル バイオテック ゲーエムベーハー | Novel RAS inhibitors |
| CN115448860B (en) * | 2022-09-16 | 2024-04-02 | 上海海客宜家生物科技有限公司 | Synthesis method of o-methylthio benzonitrile |
| WO2024175659A1 (en) | 2023-02-23 | 2024-08-29 | KHR Biotec GmbH | 3ah-cyclopenta[b]benzofuran-3a-yl as ras inhibitors |
| WO2024175662A1 (en) | 2023-02-23 | 2024-08-29 | KHR Biotec GmbH | Flavagline derivatives as ras inhibitors |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19934952A1 (en) | 1998-07-30 | 2000-02-03 | Novartis Ag | New cyclopenta-benzofuran derivatives, used as pesticides, especially insecticides and acaricides for plant protection |
| DE10356218A1 (en) | 2003-12-03 | 2005-06-30 | Bayer Cropscience Ag | A method for identifying fungicidally active compounds based on pyruvate kinases from fungi |
| CA2560740A1 (en) | 2004-03-23 | 2006-10-06 | Trustees Of Boston University | Synthesis of rocaglamide natural products via photochemical generation of oxidopyrylium species |
| DE102004024504A1 (en) | 2004-05-18 | 2006-02-16 | Bayer Healthcare Ag | Novel cylopenta [b] benzofuran derivatives and their use |
| WO2006007634A1 (en) | 2004-07-16 | 2006-01-26 | Cerylid Biosciences Ltd | Processes and intermediates |
| EP1693059A1 (en) | 2005-02-22 | 2006-08-23 | Deutsches Krebsforschungszentrum | Use of rocaglamide derivatives as NF-AT-specific inhibitors for the treatment of certain inflammatory diseases |
| CN100418532C (en) | 2005-06-17 | 2008-09-17 | 吕志民 | NF-kB compound inhibitor for treating various diseases |
| CA2652873A1 (en) | 2006-05-22 | 2007-12-06 | Trustees Of Boston University | Asymmetric synthesis of rocaglamides via enantioselective photocycloaddition mediated by chiral bronsted acids |
| EP2189453A1 (en) | 2008-11-25 | 2010-05-26 | Université Louis Pasteur | Rocaglaol derivatives as cardioprotectant agents |
| WO2011140334A2 (en) | 2010-05-06 | 2011-11-10 | Trustees Of Boston University | Compounds, methods of making or identifying compounds, and uses thereof |
| EP2457907A1 (en) | 2010-11-16 | 2012-05-30 | Université de Strasbourg | Flavagline derivatives as neuroprotective agents |
| US8669274B2 (en) * | 2010-12-13 | 2014-03-11 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitor compounds |
| US20140255432A1 (en) | 2011-07-27 | 2014-09-11 | Ohio State Innovation Foundation | Silvestrol, silvestrol analogs and uses thereof |
| WO2013170257A1 (en) | 2012-05-11 | 2013-11-14 | Dana-Farber Cancer Institute, Inc. | Treating muc1-expressing cancers with helicase inhibitors |
| EP3021842A1 (en) | 2013-07-17 | 2016-05-25 | Deutsches Krebsforschungszentrum | Sensitization of cancer cells to apoptosis induction by flavaglines and 5-hydroxy-flavones |
| EP3071234A1 (en) | 2013-11-22 | 2016-09-28 | Deutsches Krebsforschungszentrum | Translation inhibitors in high-dose chemo- and/or high-dose radiotherapy |
| FR3023290B1 (en) | 2014-07-04 | 2016-08-19 | Pf Medicament | DERIVATIVES OF FLAVAGLINES |
| CN108601788B (en) * | 2015-11-25 | 2021-10-22 | 效应治疗股份有限公司 | EIF 4A-inhibiting compounds and methods relating thereto |
-
2016
- 2016-11-22 CN CN201680069164.7A patent/CN108601788B/en active Active
- 2016-11-22 EP EP16869174.9A patent/EP3380101B1/en active Active
- 2016-11-22 MY MYPI2018701976A patent/MY196749A/en unknown
- 2016-11-22 DK DK16869174.9T patent/DK3380101T3/en active
- 2016-11-22 SG SG11201804132UA patent/SG11201804132UA/en unknown
- 2016-11-22 US US15/358,761 patent/US9957277B2/en active Active
- 2016-11-22 PE PE2018001027A patent/PE20181303A1/en unknown
- 2016-11-22 SG SG10202004793YA patent/SG10202004793YA/en unknown
- 2016-11-22 DK DK21153153.8T patent/DK3888658T3/en active
- 2016-11-22 JP JP2018526874A patent/JP7105691B2/en active Active
- 2016-11-22 WO PCT/US2016/063353 patent/WO2017091585A1/en active Application Filing
- 2016-11-22 NZ NZ743453A patent/NZ743453A/en unknown
- 2016-11-22 AU AU2016359617A patent/AU2016359617B2/en active Active
- 2016-11-22 EA EA201891229A patent/EA037370B1/en unknown
- 2016-11-22 ES ES21153153T patent/ES2974439T3/en active Active
- 2016-11-22 MX MX2018006443A patent/MX2018006443A/en unknown
- 2016-11-22 FI FIEP21153153.8T patent/FI3888658T3/en active
- 2016-11-22 ES ES16869174T patent/ES2870037T3/en active Active
- 2016-11-22 KR KR1020187017797A patent/KR20180096644A/en not_active Application Discontinuation
- 2016-11-22 CA CA3006041A patent/CA3006041A1/en active Pending
- 2016-11-22 EP EP21153153.8A patent/EP3888658B1/en active Active
- 2016-11-23 TW TW105138486A patent/TWI731899B/en active
-
2018
- 2018-03-12 US US15/917,973 patent/US10577378B2/en active Active
- 2018-05-16 IL IL259433A patent/IL259433B/en active IP Right Grant
- 2018-05-18 PH PH12018501073A patent/PH12018501073A1/en unknown
- 2018-05-25 CL CL2018001411A patent/CL2018001411A1/en unknown
- 2018-06-18 ZA ZA2018/04070A patent/ZA201804070B/en unknown
- 2018-06-22 CO CONC2018/0006475A patent/CO2018006475A2/en unknown
-
2020
- 2020-02-28 US US16/804,937 patent/US11440917B2/en active Active
-
2022
- 2022-04-14 US US17/720,529 patent/US20230071483A1/en active Pending
-
2023
- 2023-05-26 US US18/324,616 patent/US20230295179A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201804132UA (en) | Eif4-a-inhibiting compounds and methods related thereto | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201908532UA (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
| SG11201908604YA (en) | Fused imidazo-piperidine jak inhibitor compound | |
| SG11201903487SA (en) | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF | |
| SG11201809714TA (en) | Piperidines as menin inhibitors | |
| SG11201804647TA (en) | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201804312RA (en) | Microbubble-chemotherapeutic agent complex for sonodynamic therapy | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201807301SA (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201810522UA (en) | Anti-cd40 antibodies and their uses | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201403402VA (en) | Compounds | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201900405XA (en) | Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia | |
| SG11201909376TA (en) | Crystalline forms of a jak inhibitor compound | |
| SG11201909615YA (en) | Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same | |
| SG11201407591PA (en) | Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof | |
| SG11201804123VA (en) | Modulators of kv3 channels to treat pain | |
| SG11201811686UA (en) | 18f-labeled triazole containing psma inhibitors |